Stock Pick

Buy, hold, sell: Goodman Group, Endeavour, Resmed shares

Written by

openjargon

in

A woman leans forward with her hand behind her ear, as if trying to hear information.

S&P/ASX 200 Index (ASX: XJO) shares are down 0.5% to 8,757.9 points on Wednesday.

Among the 11 market sectors, energy is in the lead today, up 2.9%, while materials is the laggard, down 2.3%. 

Meanwhile, on The Bull, three experts give us their views on three ASX 200 shares.

Let’s check them out.   

Resmed CDI (ASX: RMD)

Resmed shares are $31.37 apiece, down 0.2% on Wednesday.

The Resmed share price fell 26.6% to $28.88 in FY26 amid a broader healthcare sector downturn.

Blake Halligan from Catapult Wealth has a buy rating on this ASX 200 healthcare share.

Halligan said:

ResMed is a global leader in sleep apnoea devices and digital health platforms, benefiting from strong structural demand and resilient clinical positioning.

Despite the progression in GLP-1 therapies for treating sleep apnoea, ResMed’s CPAP (continuous positive airway pressure) treatments remain superior at this point in time.

RMD continues to offer appealing growth, income and defensive healthcare exposure.

Goodman Group (ASX: GMG)

The Goodman Group share price is $30.07, down 2% today.

Goodman Group shares fell 9.1% in FY26 and finished the year at $31.13 on 30 June.

Remo Greco from Sanlam Private Wealth has a hold rating on this ASX 200 real estate investment trust (REIT).

Greco said: 

Goodman Group is a global industrial property and data centre developer. Data centres under construction represent 73 per cent of work in progress, according to the company’s third quarter update in fiscal year 2026.

In our view, GMG trades at an elevated valuation, reflecting a lot of potential growth options for the business. The shares have risen from $25.08 on March 30 to trade at $30.645 on July 2.

Investors can continue holding the stock after a recent strong share price performance, but should monitor the news flow to gauge if developments are meeting investor expectations.

Endeavour Group Ltd (ASX: EDV)

Endeavour shares are $3.41 apiece, up 1.6% today.

The Endeavour share price fell 19% to close out FY26 at $3.25 on 30 June.

James Bills from Shaw and Partners has a sell rating on this ASX 200 consumer staples share. 

Bills said: 

Endeavour operates liquor outlets, hotels and gaming facilities. It’s navigating a more challenging consumer environment amid cost pressures in fiercely competitive sectors.

While the company has a strong asset base and market position, we believe near term performance is likely to remain subdued.

With limited catalysts for a re-rating, the stock lacks appeal at this stage of the cycle, in our view.

The shares have fallen from $4.04 on March 2 to trade at $3.375 on July 2.

 

The post Buy, hold, sell: Goodman Group, Endeavour, Resmed shares appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now…

See the 5 Stocks

* Returns as of 16 June 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goodman Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More posts